(UroToday.com) The NIVOREN GETUG-AFU26 clinical trial was a real-world phase 2 multicenter study of nivolumab in metastatic clear cell renal cell carcinoma (ccRCC). Patient outcomes from this study compared favorably to the randomized phase 3 trial CheckMate 025 comparing nivolumab with everolimus, published in 2015. From the NIVOREN trial, a translational program was launched to assess molecular features associated with response to nivolumab. A total of 324 patients had molecular data generated for inclusion in this ancillary study.